WEBINAR: Bridging the gap: using organ-on-a-chip as an experimental tool to develop (cost) effective therapeutics – Tuesday, 26 September 2023

cnb887 dtr webinar promo bar v1 |
Register here
cn-bio-organ-on-a-chip-logo cn-bio-organ-on-a-chip-logo cn-bio-organ-on-a-chip-logo cn-bio-organ-on-a-chip-logo
  • Products
    • Explore our solutions


      PhysioMimix® products enable you to recreate complex human biology and accurately predict human drug responses

      PhysioMimix OOC

      PhysioMimix OOC systems
      Learn more

      Consumables

      • Multi-chip plates
      • 3D validated cells
      • NASH-in-a-box
      Learn more

      Models

      • Single-organ models
      • Liver-on-a-chip model
      • Multi-organ models

      Support packages

      • PhysioMimix® support packages
  • Applications
    • Discover the applications


      Investigate the application areas that our PhysioMimix® products and services support

      Learn more

      Disease modeling

      • Non-Alcoholic Steatohepatitis
      • Hepatitis B
      • COVID-19
      Learn more

      Safety toxicology

      • Drug-induced liver injury
      • Immune-mediated toxicities
      Learn more

      ADME

      • Drug absorption
      • Drug metabolism
      • Drug bioavailability
      Learn more
  • Services
    • Studies as a service


      Our team will work collaboratively with you to design a study around your research goals and generate actionable data within weeks

      Learn more
      NAFLD / NASH icons

      NAFLD / NASH

      Drug-induced liver injury icon

      Drug-induced liver injury

      icon adme |

      ADME

  • Resources
  • Company
    • About us


      Meet the team, explore our culture and discover what to expect when working with us

      CN Bio team photo
      About us

      Latest news

      • A guide to pre-validating cells for use in Organ-on-a-chip assays

      • CN Bio and LifeNet Health LifeSciences partner to supply validated primary human cells for microphysiological systems

      • CN Bio appoints Dr. Tomasz Kostrzewski as Chief Scientific Officer

      View all news

      Upcoming Events

      • AASLD 2023

      • EUROTOX 2023

      View all events

      Join the team!

      • Content Marketing Manager

      • Senior Scientist R&D

      View all jobs
  • Contact
  • Products
    • PhysioMimix® OOC Microphysiological Systems
    • Consumables
      • PhysioMimix® multi-chip plates
      • 3D validated cells
      • NASH-in-a-box
    • Organ-on-a-chip models
    • Support packages
  • Applications
    • Disease modeling
    • Safety toxicology
    • ADME
  • Services
    • Non-Alcoholic Steatohepatitis
    • Drug-Induced Liver Injury
    • ADME
  • Resources
  • Company
    • About us
    • Events
    • News
    • Careers
  • Contact
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
Chat live with an expert

News

January 12, 2015

CN Bio announces opening of new Biosafety Level 3 facility

CN Bio Innovations Ltd (CN Bio), an expert in developing human biomimetic platforms to test and develop therapeutics for serious diseases, announced

Category iconPress releases

November 17, 2014

CN Bio hosts popular Investigator Meeting and presents new HBV data at AASLD 2014

CN Bio Innovations’ (CN Bio) Investigator Meeting entitled “Hepatitis B: New models pave the way to a cure” was held on Monday 10th November 2014 at

Category iconBusiness

October 28, 2014

NIH Director highlights LiverChip in Compton Lecture

Dr Francis S. Collins, Director of the US National Institutes of Health (NIH), highlighted LiverChip during the 2014 Karl Taylor Compton Lecture on

Category iconBusiness

September 17, 2014

TSB Funds New Research by CN Bio into Fatty Liver Disease

CN Bio Innovations (CN Bio) announced today the receipt of a 12 months funding award from the UK’s Technology Strategy Board (TSB) for the development

Category iconBusiness

September 2, 2014

Imperial College London to present first public HBV data from CN Bio in vitro liver model

CN Bio Innovations Ltd (CN Bio), an expert in developing human biomimetic platforms to test and develop therapeutics for serious diseases, has

Category iconPress releases

July 28, 2014

CN Bio Innovations marks World Hepatitis Day by signing research agreement with Imperial College London

Collaboration will develop and further validate CN Bio’s in vitro model of Hepatitis B liver infection Oxford, UK, 28 July 2014: CN Bio Innovations

Category iconPress releases

July 14, 2014

Promotion of Dr David Hughes to the role of Chief Technology Officer

Dr David Hughes has been promoted to the role of Chief Technology Officer, effective immediately. In his new role, he will take responsibility for

Category iconBusiness

May 13, 2014

CN Bio appoints Professor Mark Thursz as Scientific Advisor

CN Bio Innovations (CN Bio) today announced the appointment of Professor Mark Thursz as a scientific advisor to the company. “Mark has considerable

Category iconBusiness

April 4, 2014

CN Bio hires Director of Licensing

CN Bio Innovations (CN Bio) announced today the appointment of Gavin Clark to the role of Director of Licensing. This is a new position created to

Category iconBusiness

Primary Sidebar

Filter news

Speak to our experts

Speak directly with one of our OOC experts to see how our products and services can support your studies

Request a meeting

Footer

CN Bio logo

332 Cambridge Science Park, Milton Road
Cambridge, CB4 0WN

UK: +44 (0) 1223 737 941

US: +1 415 523 4005

Privacy | Cookies | Terms | Regulatory | Accessibility

Product Recycling

©2023 CN Bio Innovations Ltd
Registered No. ‍06517359. VAT No. GB978184563

Latest news

  • A guide to pre-validating cells for use in Organ-on-a-chip assays September 5, 2023
  • CN Bio and LifeNet Health LifeSciences partner to supply validated primary human cells for microphysiological systems September 5, 2023
  • CN Bio appoints Dr. Tomasz Kostrzewski as Chief Scientific Officer August 30, 2023

Upcoming events

AASLD 2023 November 10-14, 2023

EUROTOX 2023 September 10-13, 2023